Could a vaccine stop lung cancer before it starts?
NCT ID NCT07169617
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a vaccine called SurVaxM in 80 current or former heavy smokers at high risk for lung cancer. The vaccine trains the immune system to recognize and attack cells that produce a protein called survivin, which is common in cancer cells. The goal is to see if the vaccine can trigger antibodies that may prevent lung cancer from developing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SurVaxM (survivin peptide vaccine) with montanide and sargramostim
What this could lead to
If it works, this could point toward a vaccine that prevents lung cancer in people at high risk, like heavy smokers.
What could go wrong
This is an early phase II trial with only 80 participants, so results may not apply broadly. The vaccine may not trigger a strong enough immune response or prevent cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Tennessee - Knoxville
Knoxville, Tennessee, 37920, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact